Substance / Medication

Moxifloxacin

Overview

Active Ingredient
moxifloxacin
RxNorm CUI
139462

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

46 trials linked to this intervention

46
Total Trials
5
Recruiting
21
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.
Silva Denise Rossato, Fernandes Flávia Fonseca, Ferreira Juliana Carvalho et al. · J Bras Pneumol · 2025
PMID: 39813501Meta-AnalysisFull text (PMC)
Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: a systematic review and meta-analysis.
Abu-Zaid Ahmed, Alkandari Abdullah M H E, Hubail Zainab A R et al. · Front Med (Lausanne) · 2025
PMID: 41585215Meta-AnalysisFull text (PMC)
Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.
Bowen Randy C, Zhou Andrew Xingyu, Bondalapati Sailaja et al. · Br J Ophthalmol · 2018
PMID: 29326317Meta-AnalysisFull text (PMC)
Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis.
Xu Ping, Chen Hui, Xu Junchi et al. · Int J Infect Dis · 2017
PMID: 28495364Meta-Analysis
Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection.
Li Yang, Le Wen-Jing, Li Sai et al. · Int J STD AIDS · 2017
PMID: 28118803Meta-Analysis
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
Ruan Qiaoling, Liu Qihui, Sun Feng et al. · Emerg Microbes Infect · 2016
PMID: 26905025Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Moxifloxacin (substance)
SNOMED CT
412439003
UMLS CUI
C0536495
RxNorm CUI
139462

Clinical Data

This intervention maps to 19 entities in the Healos knowledge graph.

19
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
46
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.